Blocking TIM-3, LAG-3, and TIGIT can synergize with PD-1 blockade to restore the proliferative capacity of exhausted CD8+ T cells in tumors and upregulate NK cell activation, thereby enhancing tumor-killing effects (49–52). Here, HAVCR2 is linked to neoplasm.